Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Geron Corp
GERN
Alternate Symbol(s):
GERNW
Healthcare
Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the...
treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:GERN)
New Post
View:
Posts & Comments
Threaded Posts
(7)
•••
ChartEagle705
X
View Profile
View Bullboard History
Post by
ChartEagle705
on Nov 21, 2024 7:58am
Trader's notes
We’ve closed the gap—an excellent correction after the pump. The day before yesterday, there was a signal—a hammer—likely indicating a correction reversal. I see an opportunity to enter a long
...more
(7)
•••
ChartEagle705
X
View Profile
View Bullboard History
Post by
ChartEagle705
on Nov 21, 2024 7:44am
Short Short Short
The chart shows a clear downtrend, and I can see that the price has already made a new low and is now in a correction. I'm entering a short position from the $4.05 level with a stop at $4.10. I
...more
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(227)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 11, 2024 10:30pm
Geron Corporation Announces Appointment of Joseph Eid, M.D.
News; $GERN Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and DevelopmentGeron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical
...more
(253)
•••
Tulsa123
X
View Profile
View Bullboard History
Post by
Tulsa123
on Jul 29, 2024 9:18am
Glta
Should we a climb today.
(253)
•••
Tulsa123
X
View Profile
View Bullboard History
Post by
Tulsa123
on Jul 26, 2024 2:52pm
Wall Street
Absolutely think that this company has done an amazing job and the $ will go up.I hope they are correct. Glta
(253)
•••
Tulsa123
X
View Profile
View Bullboard History
Post by
Tulsa123
on Jul 26, 2024 12:16pm
The news today?
Do we see a huge gain of attention and price rise coming soon? Fabulous investment info. Good Day
(227)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 10, 2024 1:15pm
GERN Price Target Alert: $7.00. Issued by Stifel Nicolaus
News; $GERN GERN Price Target Alert: $7.00. Issued by Stifel Nicolaus2024-06-10 08:00:07 ET Stephen Willey from Stifel Nicolaus issued a price target of $7.00 for GERN on 2024-06-10 06:39:00. The
...more
(227)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 11, 2024 2:00pm
Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is '
News; $GERN Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me' | BenzingaOn CNBC@s @Mad Money Lightning Round,@ Jim Cramer said @no@ to MarineMax Inc
...more
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Mar 14, 2024 4:56pm
BUY BUY BUY BUY BUY
Tnews is good
(59)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Mar 14, 2024 4:56pm
BUY BUY BUY BUY BUY
Tnews is good
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jun 17, 2022 8:21am
GERON CORPORATION: A LOT IS RIDING ON IMETELSTAT!
$GERN Geron Corporation (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor, imetelstat, intended to treat hematologic malignancies. A lot
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden